Scientific advisory boards

BioArctic has established three Scientific Advisory Boards, with leading experts in the therapeutic areas in which the company operates. The purpose is to facilitate discussions on scientific issues and to increase the exchange of knowledge.

BioArctic has a general scientific board for discussions of issues in all our research areas. We have also established Advisory Boards for our projects in Parkinson’s disease and Complete Spinal Cord Injury. BioArctic’s Scientific Advisory Boards are composed as follows:

General scientific advisory board

  • Professor Hans Wigzell, former Vice-Chancellor of Karolinska Institutet, Sweden
  • Professor Martin Ingelsson, Uppsala University, Sweden
  • Dr. Staffan Pauli, CEO Mabtech AB, Sweden

Scientific advisory board – Alzheimer’s disease

BioArctic has a long tradition of research focusing on Alzheimer’s disease and develops new innovative treatments in close collaboration with leading expert in the field. BAN2401 is the lead drug candidate.

Scientific advisory board – Parkinson’s disease

  • Professor Ken Marek, Yale University, USA
  • Professor Kaj Blennow, University of Gothenburg, Sweden
  • Professor Martin Ingelsson, Uppsala University, Sweden

Scientific advisory board – Complete spinal cord injury

  • Professor Mikael Svensson, Karolinska Institutet, Sweden
  • Professor Lars Olson, Karolinska Institutet, Sweden
  • Associate Professor Elisabeth Åkesson, Karolinska Institutet, Sweden
  • Associate Professor Per Mattsson, Karolinska Institutet, Sweden
  • Dr. Claes Hultling, Karolinska Institutet, Sweden